Communication of Survival Data in US Food and Drug Administration-Approved Labeling of Cancer Drugs.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 34251420.
- Also identified by DOI 10.1001/jamainternmed.2021.3505 and PMC identifier 8276121.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cross-sectional study examines how information on overall survival benefits of novel cancer drug indications is communicated in labeling.
Medical subject headings
- Antineoplastic Agents
- Data Display
- Drug Labeling
- Neoplasms
- Research Design